Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-02-2016 | Cornea

Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome

Authors: Merle Fernandes, Divya Vira, Radhika Medikonda, Nagendra Kumar

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 2/2016

Abstract

Background

Emergence of multi-drug resistant (MDR), extensively drug resistant (XDR), and pan-drug resistant (PDR) strains of Pseudomonas aeruginosa pose a significant therapeutic challenge. Managing XDR and PDR Pseudomonas aeruginosa keratitis would be extremely difficult due to paucity of safe and effective topical medications. We aim to describe the clinical features, risk factors, and outcome of XDR and PDR Pseudomonas aeruginosa keratitis.

Methods

A retrospective chart review of consecutive cases of XDR and PDR Pseudomonas aeruginosa keratitis were identified from Ocular Microbiology Department. XDR and PDR were defined based on criteria established by Centers for Disease Control and European Centre for Disease Prevention and Control. The following data was collected: age, gender, occupation, symptom duration, systemic and ocular risk factors, infiltrate characteristics, antimicrobial susceptibility, complications, surgical interventions, presenting, and final visual acuity and final outcome. Complete success was defined as resolution of the infiltrate with scar formation on medical treatment alone. Partial success was the resolution following tissue adhesive application. Failure was an inadequate response to medical therapy with progressive increase in infiltrate, corneal melting, and/or perforation necessitating one or more therapeutic penetrating keratoplasties or evisceration.

Results

Fifteen eyes of 13 patients were included. Seven (53.8 %) were male with left eye involvement in nine (60 %) cases. Most common risk factors were bandage contact lens (6, 40 %), topical steroids (5, 33.3 %), previous therapeutic graft (4, 26.6 %), and ocular surface disorder (OSD) following Stevens Johnson Syndrome (SJS) (4, 26.6 %). Of 15 isolates, six (40 %) were sensitive only to imipenem, three (20 %) to colistin, two (13.3 %) to neomycin, one (6.7 %) each to imipenem and colistin, imipenem and ceftazidime, and azithromycin respectively. One isolate was resistant to all antibiotics. Complete success was noted in two (16.67 %), partial success in three (25 %) and failure in seven (58.33 %) eyes. Five (33.3 %) eyes healed on imipenem (three eyes), azithromycin (one eye), and imipenem and colistin (one eye).

Conclusion

XDR and PDR Pseudomonas aeruginosa keratitis are extremely difficult to treat. Globe salvage was possible in all cases; however, more than half required therapeutic grafts. Close monitoring of patients with known ocular and systemic factors is warranted.

Whitcher JP, Srinivasan M, Upadhyay MP (2001) Corneal blindness: a global perspective. Bull World Health Organ 79:214–21PubMedPubMedCentral

Gopinathan U, Sharma S, Garg P, Rao GN (2009) Review of epidemiological features, microbiological diagnosis and treatment outcome of microbial keratitis: experience of over a decade. Ind J Ophthalmol 57(4):273–79CrossRef

Bharathi M, Ramakrishna R, Shivakumar C, Meenakshi R, Lionalraj D (2010) Etiology and antibacterial susceptibility pattern of community acquired bacterial ocular infections in a tertiary eye care hospital in south India. Ind J Ophthalmol 58(6):497–507CrossRef

Garg P, Sharma S, Rao GN (1999) Ciprofloxacin-resistant pseudomonas keratitis. Ophthalmology 106:1319–1323PubMedCrossRef

Jhanji V, Sharma N, Satpathy G, Titiyal J (2007) Fourth-generation fluoroquinolone resistant bacterial keratitis. J Cataract Ref Surg 33:1488–89CrossRef

Park SH, Lim JA, Choi JS, Kim KA, Joo CK (2009) The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics. Cornea 28:68–72PubMedCrossRef

Nordmann P, Naas T, Fortineau N, Poirel L (2007) Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010. Curr Opin Microbiol 10(5):436–40PubMedCrossRef

Magiorakos AP, Srinivasan R, Carey RB, Carmell Y, Falagas MR, GIske CG et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Inf 18:268–281CrossRef

Ku JY, Kim P, Tong J, Wechsler A, McCluskey P (2010) Multiresistant Pseudomonas keratitis. Clin Exp Ophthalmol 38(8):818–819CrossRef

10.

Jain R, Murthy SI, Motukupally SR (2014) Clinical outcomes of corneal graft infections caused by multi-drug resistant Pseudomonas aeruginosa. Cornea 33(1):22–26PubMedCrossRef

11.

Chaurasia S, Ramappa M, Ashar J, Sharma S (2014) Neonatal infectious keratitis. Cornea 33(7):673–676PubMedCrossRef

12.

Jain R, Murthy SI, Motukupally SR, Jain M (2014) Use of topical colistin in multiple drug resistant Pseudomonas aeruginosa bacterial keratitis. Cornea 33(9):923–927PubMedCrossRef

13.

Sharma S, Gopalakrishnan S, Aasuri MK, Garg P, Rao GN (2003) Trends in contact lens-associated microbial keratitis in South India. Ophthalmology 110:138–143PubMedCrossRef

14.

Dart JKG, Seal DV (1988) Pathogenesis and therapy of Pseudomonas aeruginosa keratitis. Eye 2(Suppl):S46–S55PubMedCrossRef

15.

American Academy of Ophthalmology Cornea/External Disease Panel (2013) Bacterial keratitis preferred practice pattern. American Academy of Ophthalmology 1–42

16.

Hooper DC (2000) Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Inf Dis 31(Suppl 2):S24–8CrossRef

17.

Oldenburg CE, Prajna L, Srinivasan M, Rajaraman R, Ravindran M, Mascarenhas J et al (2013) Emerging Moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India. Ophthalmic Epidemiol 20(3):155–158PubMedPubMedCentralCrossRef

18.

Bodro M, Sabe N, Tubau F, Llado L, Baliellas C, Gonzalez-Costello J et al (2014) Extensively drug resistant Pseudomonas aeruginosa bacteremia in solid organ transplant. Transplantation 99(3):616–22CrossRef

19.

Bourcier T, Thomas F, Borderie V, Chaumeil C, Laroche L (2003) Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. Br J Oophthalmol 87:834–838CrossRef

20.

Bharati JM, Ramakrishnan R, Meenakshi R, Shivakumar C, Raj DL (2009) Analysis of the risk factors predisposing to fungal, bacterial, and Acanthamoeba keratitis in south India. Indian J Med Res 130:749–757

21.

Stapleton F, Carnt N (2012) Contact lens-related microbial keratitis: how have epidemiology and genetics helped us with pathogenesis and prophylaxis. Eye 26:185–193PubMedPubMedCentralCrossRef

22.

Stapleton F, Keaty L, Edwards K, Naduvilath T, Dart JK, Brian G et al (2008) The incidence of contact lens-related microbial keratitis in Australia. Ophthalmology 115:1665–1662CrossRef

23.

Bruinsma GM, van der Mei HC, Busscher HJ (2001) Bacterial adhesion to surface hydrophilic and hydrophobic contact lenses. Biomaterials 22:3217–3224PubMedCrossRef

24.

Tam C, Mun JJ, Evans DJ, Fleiszig SMJ (2010) The impact of inoculation parameters on pathogenesis of contact lens-related infectious keratitis. Invest Ophthalm Vis Sci 51:3100–3106CrossRef

25.

Ho PC, Elliott JH (1975) Kinetics of corneal epithelial regeneration.II. Epidermal growth factor and topical corticosteroids. Investig Ophthalmol 14(8):630–633

26.

No authors listed (2007) The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye Workshop. Ocular Surf 5: 93–107

27.

Jhanji V, Constantinou M, Taylor HR, Vajpayee RB (2009) Microbiological and clinical profiles of patients with microbial keratitis residing in nursing homes. Br J Ophthalmol 93:1639–1642PubMedCrossRef

28.

Sotozono C, Inagaki K, Fujita A, Koizumi N, Sano Y, Inatomi T et al (2002) Methicillin-resistant Staphylococcus aureus and Methicillin-resistant Staphylococcus epidermidis in the cornea. Cornea 21(Suppl 2):S94–S101PubMedCrossRef

29.

Nation RL, Li J (2009) Colistin in the 21st Century. Curr Opin Infect Dis 22(6):535–543PubMedPubMedCentralCrossRef

30.

Equi A, Balfour-Lynn IM, Bush A, Rosenthal M (2002) Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial. Lancet 360:978–84PubMedCrossRef

31.

Bala A, Kumar R, Harjai K (2011) Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections. J Med Microbiol 60:300–306PubMedCrossRef

Title: Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome
Authors: Merle Fernandes
Divya Vira
Radhika Medikonda
Nagendra Kumar
Publication date: 01-02-2016
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 2/2016
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-015-3208-7

At a glance: The STEP trials

Springer Medicine

Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2016

Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study

Marked dissociation of photopic and mesopic contrast sensitivity even in normal observers

25-gauge pars plana vitrectomy with medium-term postoperative perfluoro-n-octane for the repair of giant retinal tears

Small-incision lenticule extraction (SMILE): outcomes of 722 eyes treated for myopia and myopic astigmatism

Combined intravitreal melphalan and intravenous/intra-arterial chemotherapy for retinoblastoma with vitreous seeds

A modified scleral dissection technique with suprachoroidal drainage for canaloplasty